澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

RADIOPHARM THERANOSTICS LTD

0.010

-0.001-9.09%

成交量：61.77萬

成交額：6,705

市值：4,337.55萬

市盈率：-0.53

高：0.011

開：0.011

低：0.010

收：0.011

52周最高：0.040

52周最低：0.009

股本：43.38億

流通股本：33.43億

量比：0.03

換手率：0.02%

股息：- -

股息率：- -

每股收益(TTM):-0.019

每股收益(LYR):-0.018

淨資產收益率：-92.10%

總資產收益率：-28.33%

市淨率：0.84

市盈率(LYR):-0.54

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Radiopharm Theranostics公司Rad202研究獲臨床概念驗證安全性與生物分佈數據積極

Radiopharm Theranostics獲數據安全監查委員會積極推薦，177Lu-Rad202一期HEAT臨床試驗推進至第4隊列

Radiopharm Theranostics：推進RAD202一期臨床試驗至180Mci劑量，針對HER2陽性晚期實體瘤

Radiopharm Theranostics定於2026年10月1日召開FDA二期結束會議，為Rad101三期試驗鋪路

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/RAD.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.01,"timestamp":1787638320000,"preClose":0.011,"halted":0,"volume":617704,"delay":0,"changeRate":-0.09090909090909084,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4337549000,"eps":-0.019034,"marketStatus":"未開盤","change":-0.001,"latestTime":"08-25 16:12:00 AEST","open":0.011,"high":0.011,"low":0.01,"amount":6705,"amplitude":0.090909,"askPrice":0.011,"askSize":1300706,"bidPrice":0.01,"bidSize":910000,"shortable":3,"etf":0,"ttmEps":-0.019034,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.011,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.03173548536838123,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.01,"auctionPrice":0.011,"auctionVolume":1,"auction":3,"marketStatus":"盘后竞价","timestamp":1787551205386}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-28.33%","roe":"-92.10%","lyrEps":-0.018424,"volumeRatio":0.03173548536838123,"shares":4337549000,"dividePrice":0,"high":0.011,"amplitude":0.090909,"preClose":0.011,"low":0.01,"week52Low":0.009,"pbRate":"0.84","psRate":"2.66","week52High":0.04,"institutionHeld":0,"latestPrice":0.01,"committee":-0.176734,"eps":-0.019034,"divideRate":0,"volume":617704,"delay":0,"ttmEps":-0.019034,"open":0.011,"prevYearClose":0.025,"prevWeekClose":0.01,"prevMonthClose":0.014,"prevQuarterClose":0.019,"fiveDayClose":0.012,"twentyDayClose":0.015,"sixtyDayClose":0.021,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1119579747","title":"Radiopharm Theranostics公司Rad202研究獲臨床概念驗證 安全性與生物分佈數據積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1119579747","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119579747?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 19:02","pubTimestamp":1787223725,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司公布了一项关于其候选药物Rad202的最新研究成果。该研究结果标志着该药物在临床试验中取得了重要的概念验证，其安全性和生物分布方面的表现均呈现积极态势。具体而言，这项研究为Rad202的后续开发奠定了坚实基础。它不仅验证了Rad202的科学原理，也进一步增强了市场对公司研发管线和整体技术平台的信心。公司认为，这一进展将有助于推动该候选药物进入下一阶段的临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171695853","title":"Radiopharm Theranostics獲數據安全監查委員會積極推薦，177Lu-Rad202一期HEAT臨床試驗推進至第4隊列","url":"https://stock-news.laohu8.com/highlight/detail?id=1171695853","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171695853?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 19:01","pubTimestamp":1787223679,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics宣布，其数据安全监查委员会已给出积极推荐意见，同意177Lu-Rad202一期HEAT临床试验向前推进至第4队列。这一关键进展标志着该研究项目迈入新的阶段，为后续研发铺平了道路。委员会基于现有数据的安全性和可行性评估，作出了支持继续推进的决定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192885524","title":"Radiopharm Theranostics：推進RAD202一期臨床試驗至180Mci劑量，針對HER2陽性晚期實體瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1192885524","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192885524?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 19:01","pubTimestamp":1787223676,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics宣布，其RAD202一期临床试验已推进至180Mci剂量水平，该试验针对HER2阳性晚期实体瘤患者。这一进展标志着公司在放射性药物开发领域的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107926876","title":"Radiopharm Theranostics定於2026年10月1日召開FDA二期結束會議，為Rad101三期試驗鋪路","url":"https://stock-news.laohu8.com/highlight/detail?id=1107926876","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107926876?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:31","pubTimestamp":1786966268,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司已正式敲定，将于2026年10月1日与美国食品药品监督管理局（FDA）举行一场关键的二期结束会议。此次会议的核心议题，是围绕其备受瞩目的Rad101药物所即将启动的三期临床试验展开深入磋商与交流。这一重要日程的安排，标志着该公司在推进其放射性药物管线进程中，又迈出了具有战略意义的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RAD.AU\",params:#limit:6,delay:true,,,undefined,":[]}}